Glycogen synthase kinase-3β in patients with bipolar I disorder: results from a prospective study

Autor:	Helena Gp Joaquim, Anne Sophie Jacoby, Maj Vinberg, Klaus Munkholm, Lars Vedel Kessing, Wagner F. Gattaz, Leda Leme Talib
Rok vydání:	2016
Předmět:	Adult Male medicine.medical_specialty Bipolar I disorder Bipolar Disorder Lithium (medication) Statistics as Topic Behavioral Symptoms Lithium 03 medical and health sciences 0302 clinical medicine GSK-3 Internal medicine Interview Psychological medicine Humans Bipolar disorder Prospective Studies Prospective cohort study GSK3B Biological Psychiatry Glycogen Synthase Kinase 3 beta medicine.disease Confidence interval 030227 psychiatry Psychiatry and Mental health Female medicine.symptom Psychology Mania 030217 neurology & neurosurgery Clinical psychology medicine.drug
Zdroj:	Bipolar disorders. 18(4)
ISSN:	1399-5618
Popis:	Objectives The enzyme glycogen synthase kinase-3β (GSK3β) is involved in the mechanisms of action of lithium and may play a role in relation to affective states in bipolar disorder. The objectives of the present study were to compare the activity of GSK-3β (measured as levels of phosphorylated GSK-3β [p-GSK-3β]) between patients with bipolar disorder in the euthymic state and healthy control subjects, and to investigate whether GSK-3β activity varies with affective states in patients with bipolar I disorder. Methods In a prospective 6–12-month follow-up study, we investigated state-specific, intraindividual alterations in the activity of GSK-3β in 60 patients with bipolar I disorder with an acute severe manic index episode and in subsequent euthymic, depressive and manic states and compared this with repeated measurements in healthy control subjects. Data were analyzed using linear mixed-effects models. Results From baseline to the end of follow-up, blood samples were drawn from the 60 patients during 181 affective states, comprising 60 manic, 11 mixed, 23 depressive, and 87 states of euthymia. A total of 69 blood samples were drawn from 35 healthy control subjects, with two samples from the same subject taken three months apart. In mixed-model analysis, p-GSK-3β was decreased in the euthymic state of subjects with bipolar disorder compared with healthy control subjects (b=0.63, 95% confidence interval [CI]: 0.42–0.96, P=.03). In addition, p-GSK-3β varied with affective states, being increased in depressive (b=1.68, 95% CI: 1.08–2.62, P=.02) and mixed (b=2.07, 95% CI: 1.12–3.84, P=.02) states but not in mania compared with euthymia. Conclusions The activity of GSK-3β is altered in euthymic bipolar disorder compared with healthy control subjects and varies with affective states.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3023ec49ac407fc1ce2d9a3588262a06 https://pubmed.ncbi.nlm.nih.gov/27440170 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.